5-Methoxy-diisopropyltryptamine

5-Methoxy-diisopropyltryptamine
Systematic (IUPAC) name
3-[2-(Diisopropylamino)ethyl]-5-methoxyindole
Clinical data
Pregnancy cat.  ?
Legal status  ? (UK) Schedule I (US)
Identifiers
CAS number 4021-34-5 Y
ATC code  ?
PubChem CID 151182
DrugBank DB01441
ChemSpider 133247 Y
ChEBI CHEBI:48282 Y
Chemical data
Formula C17H26N2O 
Mol. mass 274.4
SMILES eMolecules & PubChem
Physical data
Melt. point 181 °C (358 °F)
 Y(what is this?)  (verify)

5-methoxy-diisopropyltryptamine (5-MeO-DiPT) is a tryptamine psychedelic used as a recreational drug under the street names "foxy" and "foxy methoxy". 5-MeO-DiPT is orally active, and dosages between 6–20 mg are commonly reported. Many users note an unpleasant body load accompanies higher dosages. 5-MeO-DiPT is also taken by insufflation, or sometimes it is smoked or injected. Some users also report sound distortion, also noted with the related drug, DiPT.

Contents

Effects

Erowid reports the following effects:[1]

Positive

Neutral(or positive)

Negative

Overdosage

Excessive doses have caused clinical intoxication, characterized by nausea, vomiting, agitation, hypotension, mydriasis, tachycardia and hallucinations, in a number of young adults. Rhabdomyolysis and renal failure occurred in one young man and another one died 3-4 hours after an apparent rectal overdose.[2]

Legality

5-MeO-DIPT has been illegal in Germany since September 1999, Greece since February 2003, Denmark since February 2004, Sweden since October 2004, Japan since April 2005, and Singapore since early 2006.

On April 4, 2003, the United States DEA added both 5-MeO-DiPT and AMT to Schedule I of the Controlled Substances Act under "emergency scheduling" procedures. The drugs were officially placed into Schedule I on September 29, 2004.

Prior to its prohibition in the U.S., 5-MeO-DiPT was sold online alongside psychoactive analogues like DiPT, and DPT neither of which have yet been expressly outlawed in that country. However, in July 2004, Operation Web Tryp was concluded, confirming that U.S. Federal law enforcement intends to prosecute sale of these analogs of 5-MeO-DiPT. Previous prosecutions under the Federal Analog Act have met, on occasion, with failure, given some court rulings regarding possible unconstitutional vagueness regarding what substances are properly considered 'analogs'; such issues may be addressed on appeal.

See also

External links

References

  1. ^ Erowid 5-MeO-DIPT Vault : Effects
  2. ^ R. Baselt, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 975-976.